Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

Open access
Oriol, A., Vives, S., Hernandez-Rivas, J. M., Tormo, M., Heras, I., Rivas, C., Bethencourt, C., Moscardo, F., Bueno, J., Grande, C., del Potro, E., Guardia, R., Brunet, S., Bergua, J., Bernal, T., Moreno, M. J., Calvo, C., Bastida, P., Feliu, E., Ribera, J. M., for the Programa Espanol de Tratamiento en Hematologia (PETHEMA) Group · 2010 · Haematologica

Abstract

BACKGROUND: About one half of adults with acute lymphoblastic leukemia are not cured of the disease and ultimately die. The objective of this study was to explore the factors influencing the outcome of adult patients with relapsed acute lymphoblastic leukemia. DESIGN AND METHODS: We analyzed the characteristics, the outcome and the prognostic factors for survival after first relapse in a series of 263 adult patients with acute lymphoblastic leukemia (excluding those with mature B-cell acute lymphoblastic leukemia) prospectively enrolled in four consecutive risk-adapted PETHEMA trials. RESULTS: The median overall survival after relapse was 4.5 months (95% CI, 4-5 months) with a 5-year overall survival of 10% (95% CI, 8%-12%); 45% of patients receiving intensive second-line treatment achieved a second complete remission and 22% (95% CI, 14%-30%) of them remained disease free at 5 years. Factors predicting a good outcome after rescue therapy were age less than 30 years (2-year overall survival of 21% versus 10% for those over 30 years old; P<0.022) and a first remission lasting more than 2 years (2-year overall survival of 36% versus 17% among those with a shorter first remission; P<0.001). Patients under 30 years old whose first complete remission lasted longer than 2 years had a 5-year overall survival of 38% (95% CI, 23%-53%) and a 5-year disease-free survival of 53% (95% CI, 34%-72%). CONCLUSIONS: The prognosis of adult patients with acute lymphoblastic leukemia who relapse is poor. Those aged less than 30 years with a first complete remission lasting longer than 2 years have reasonable possibilities of becoming long-term survivors while patients over this age or those who relapse early cannot be successfully rescued using the therapies currently available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2009.014274

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 291

Metadata

Authors
Oriol, A., Vives, S., Hernandez-Rivas, J. M., Tormo, M., Heras, I., Rivas, C., Bethencourt, C., Moscardo, F., Bueno, J., Grande, C., del Potro, E., Guardia, R., Brunet, S., Bergua, J., Bernal, T., Moreno, M. J., Calvo, C., Bastida, P., Feliu, E., Ribera, J. M., & for the Programa Espanol de Tratamiento en Hematologia (PETHEMA) Group
Venue
Haematologica
Published
2010-02-09
Volume
95
Issue
4
Pages
589-596
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2141019574
Cited by
291
References
21
FWCI
9.54
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. https://app.cochat.ai/papers/10.3324/haematol.2009.014274
The paper
Oriol, A., Vives, S., Hernandez-Rivas, J. M., Tormo, M., Heras, I., Rivas, C., Bethencourt, C., Moscardo, F., Bueno, J., Grande, C., del Potro, E., Guardia, R., Brunet, S., Bergua, J., Bernal, T., Moreno, M. J., Calvo, C., Bastida, P., Feliu, E., . . . for the Programa Espanol de Tratamiento en Hematologia (PETHEMA) Group. (2010). Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. https://doi.org/10.3324/haematol.2009.014274

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.